The role of wide-spectrum cytokeratin staining of the bone marrow cores in patients with ductal carcinoma of the breast.
The usefulness of routine pancytokeratin staining of bone marrow cores (BMCs)--negative for hematoxylin and eosin (HE)--from patients with lobular carcinoma of the breast has been fairly well established. However, the role of wide-spectrum cytokeratin staining of HE-negative BMCs from patients with ductal carcinoma has not been as well determined and is the purpose of this study. Forty-two prospectively and retrospectively reviewed He-negative BMCs from 21 patients with ductal breast carcinoma failed to reveal staining with a wide-spectrum cytokeratin stain, supporting the selective use of this immunostain in "suspicious" cases with atypical cells detected in HE BMCs.
Dunphy
C H
CH
Department of Pathology, St. Louis University Health Sciences Center, Missouri 63104, USA.
D014408:Biomarkers, Tumor / Q000032:analysis*; D001853:Bone Marrow / Q000737:chemistry / Q000473:pathology*; D019046:Bone Marrow Neoplasms / Q000737:chemistry / Q000556:secondary*; D001943:Breast Neoplasms / Q000737:chemistry / Q000473:pathology*; D018270:Carcinoma, Ductal, Breast / Q000737:chemistry / Q000556:secondary*; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D007633:Keratins / Q000032:analysis*; D011446:Prospective Studies; D012189:Retrospective Studies; D013194:Staining and Labeling
D014408:Biomarkers, Tumor; D007633:Keratins